No abstract
Introducción: en Paraguay existen pocas investigaciones que contribuyan en los procesos de diagnóstico y tratamiento del cáncer y SIDA. Objetivo: explorar y describir las estrategias de Afrontamiento y la percepción sobre Calidad de Vida y Salud de pacientes con Cáncer y Sida. Método: se recolectaron datos de 10 pacientes con Cáncer y 4 con SIDA a través del Inventario de Calidad de Vida y Salud-INCAVISA (Riveros, Sánchez-Sosa y Del Águila, 2009), el CRI-A (Moos y Moos, 1993), además de una entrevista cualitativa semi-estructurada. Resultados: La mayoría de los pacientes afronta el proceso de su enfermedad con estrategias de aproximación. Es notoria la diferencia entre los que están hospitalizados y los que llevan el tratamiento ambulatorio, donde estos últimos presentan una percepción y calificación más favorable de su Calidad de Vida. Conclusión: El estudio cualitativo mostró que el estilo de afrontamiento ha sido considerado como un factor mediador importante con relación a la adaptación a la enfermedad, son las estrategias de aproximación las que podrían, incluso, favorecer la valoración de Calidad de Vida. PALABRAS CLAVE: Afrontamiento, calidad de vida, cáncer, SIDA.
Introduction: Wrist-worn devices such as the Apple Watch have emerged as technology for tracking physical activity. The aim of this research study is to analyze the Apple Watch Series 7 (AW7) with measurements of the maximum heart rate (MHR) and maximum energy expenditure (MEE) during a maximal aerobic capacity test on the treadmill. AW7 measurements will be compared to the Polar Heart Rate Monitor (Polar) and the PARVO Metabolic Cart (PARVO). Methods: 22 healthy and active subjects (mean ± SD: age 23.8 ± 4.0 years; BMI 23.0 ± 5.9 kg/m2) volunteered for the study. The subjects confirmed their activity, health status, and were measured for body composition and aerobic capacity. Results: No significant difference was found in MEE between PARVO (109.6 ± 41.7 kcal) and AW7 (98.7 ± 24.3 kcal) conditions; t(21)=1.5, p = 0.153. In addition, there was no significant difference in MHR between PARVO (186.2 ± 16.2 BPM) and AW7 (189.3 ± 8.5 BPM) conditions; t(21)=-0.9, p = 0.379. Conclusions: The main findings of this study show that the MEE as well as the MHR between the AW7 compared to the PARVO are not different.
La educación es un derecho humano y para ello es necesario remover las múltiples barreras existentes con el fin de que ninguna persona sea excluida del sistema educativo, tal como lo establece la Ley N° 5136/2013, que garantiza un modelo educativo inclusivo. Sin embargo, a partir del análisis de la experiencia educativa de cinco adolescentes con baja visión, se constata que el paradigma predominante en las instituciones donde acuden las personas entrevistadas es el de integración, donde los estudiantes deben realizar esfuerzos por encajar dentro del sistema. Los relatos dan cuenta de que el proceso educativo -en este sentido- se ha caracterizado por un entorno poco seguro, sin accesibilidad y con múltiples barreras para el aprendizaje.
BET (bromodomain and extra-terminal) family proteins are epigenetic readers that modulate expression genes involved in cell growth and oncogenesis. Selective small molecule BET inhibitors, such as the GSK I-BETs (I-BET762, I-BET151), abrogate binding of BET proteins to acetylated chromatin and inhibit transcription of BET target genes. We and others have previously demonstrated single agent activity for BET inhibitors in a number of pre-clinical solid and hematologic tumor models. Transcriptomics and mechanistic studies from several of these tumor types indicate that BET inhibitors influence numerous signaling pathways at the transcriptional level, including RAS/RAF/MEK signaling. Here we describe the synergistic effects of combining BET and MEK inhibitors in various solid and hematologic cancer models. We observe synergistic growth inhibition and apoptosis in a subset of cell lines representing multiple tumor types, as well as patient-derived xenograft models treated with the combination ex vivo. Additionally, combination of BET and MEK inhibitors results in improved tumor growth inhibition in cell line xenograft models compared to either single agent therapy. Further exploration of the combination in sensitive tumor types highlights multiple mechanisms potentially driving synergy, and suggests possible markers associated with sensitivity to the combination. Taken together, our data highlight the potential of BET/MEK inhibitor combinations to improve upon the efficacy observed for these agents as monotherapies in a wide variety of preclinical cancer models. All studies were conducted in accordance with the GSK Policy on the Care, Welfare and Treatment of Laboratory Animals and were reviewed by the Institutional Animal Care and Use Committee either at GSK or by the ethical review process at the institution where the work was performed. Human biological samples were sourced ethically and their research use was in accord with the terms of the informed consents. Citation Format: Anastasia Wyce, Daniel J. Felitsky, Xi-Ping Zhang, Jeanne J. Matteo, Susan Korenchuk, Lijoy K. Mathew, Melissa Musso, Sakina Khaku, Victoria Ortiz, Kathryn Keenan, Melissa Stern, Yan Degenhardt, Ramona Plant, Charles F. McHugh, Peter J. Tummino, Christopher Carpenter, Olena Barbash. Broad activity for the combination of BET and MEK inhibitors across solid and hematologic cancers. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4709.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.